Advertisement

Letter From the Editor

April 2017

Dear Colleague,

This is the eighth and last edition of our newsletter titled HER2-Positive Breast Cancer Updates.

At this time, I’d like to invite you to focus on chapter 6 of our roundtable discussion video. This section focuses on pathologic complete response rate and its relationship to measuring treatment. If you haven’t watched the full video, I encourage you to do so, as I think you’ll find it to be a valuable learning experience.

I’d also like to share some articles on such important topics as the value of neoadjuvant therapy in triple-negative and HER2-positive breast cancer, how current guidelines for HER2 gene amplification testing may leave some patients at risk for misclassification and inappropriate treatment, and an insightful study that examines population-based estimates of the incidence and prognosis for patients with brain metastases at the time of diagnosis of breast cancer.

Please share this newsletter with your colleagues and don’t hesitate to get in touch with me with your comments or suggestions through the editors of the Journal of the Advanced Practitioner in Oncology, or JADPRO, at editor@advancedpractitioner.com at any time. I hope you have enjoyed receiving this newsletter over the past few months.

Heather Greene, MSN, FNP, AOCNP®
The West Cancer Center
Memphis, Tennessee

February 2017

Dear Colleague,

Welcome to the seventh edition of our HER2-Positive Breast Cancer Updates newsletter.

Today I’d like to invite you to focus on chapter 7 of our roundtable discussion video. This section focuses on the role of the nurse navigator and the importance of survivorship care. If you haven’t watched the full video, I encourage you to do so, as I think you’ll find it to be a valuable learning experience.

I’d also like to share some articles on such important topics as the fact that women treated for DCIS live longer than women with no history of DCIS, the assertion that breast density surpasses other risk factors in the development of breast cancer, and the association of osteopontin with specific prognostic factors and survival.

Please share this newsletter with your colleagues, and don’t hesitate to get in touch with me with your comments or suggestions through the editors of the Journal of the Advanced Practitioner in Oncology, or JADPRO, at editor@advancedpractitioner.com at any time.

Heather Greene, MSN, FNP, AOCNP®
The West Cancer Center
Memphis, Tennessee

January 2017

Dear Colleague,

As we start off the new year, I’d like to share the sixth edition of the HER2-Positive Breast Cancer Updates newsletter with you.

At this time, I’d like to invite you to focus on Chapter 5 of our roundtable discussion video. This section focuses on the rationale behind the use of neoadjuvant therapy from both the medical and surgical perspectives. If you haven’t watched the full video, I encourage you to do so, as I think you’ll find it to be a valuable learning experience. 

I’d also like to share some articles on such important topics as the investigative HER2-targeted dendritic cell vaccine, reducing neratinib-related toxicity, managing diarrhea in patients treated with pertuzumab, and others.

Please share this newsletter with your colleagues and don’t hesitate to get in touch with me with your comments or suggestions through the editors of the Journal of the Advanced Practitioner in Oncology, or JADPRO, at editor@advancedpractitioner.com at any time.

Best wishes for a happy and healthy 2017!


Heather Greene, MSN, FNP, AOCNP®
The West Cancer Center
Memphis, Tennessee

December 2016

Dear Colleague,

This is the fifth edition of our newsletter titled HER2-Positive Breast Cancer Updates. In this issue, we provide articles on such topics as elevated troponin levels and their association with trastuzumab-related cardiac dysfunction; how higher vitamin D levels may lead to better outcomes in patients with breast cancer; and the use of ribociclib as first-line therapy for hormone receptor-positive breast cancer. Please share this newsletter with your colleagues and don’t hesitate to get in touch with me with your comments or suggestions through the editors of the Journal of the Advanced Practitioner in Oncology, or JADPRO, at editor@advancedpractitioner.com at any time.

Until next time, take a look at the links I’ve gathered for you here. I hope you find this newsletter to be a useful resource in your practice.

Heather Greene, MSN, FNP, AOCN®
The West Cancer Center
Memphis, Tennessee 

November 2016

Dear Colleague,

Welcome to the fourth edition of our HER2-Positive Breast Cancer Updates newsletter. If you haven't yet watched the full roundtable discussion that my colleagues and I filmed recently, I invite you to take a look at Chapter 1. You'll be able to listen to the panel members share our differing perspectives on the importance of a multidisciplinary team in treating this challenging malignancy.

I've also provided articles on such topics as how breast cancers use white blood cells to avoid immune defenses; the role of CITED2 in breast carcinoma as a prognostic predictor associated with proliferation, migration, and chemoresistance; and how trastuzumab as preoperative monotherapy does not inhibit HER2 downstream signaling in HER2-positive breast cancer.

Please share this newsletter with your colleagues and don't hesitate to get in touch with me with your comments or suggestions through the editors of the Journal of the Advanced Practitioner in Oncology, or JADPRO, at editor@advancedpractitioner.com.

Until next time, take a look at the links I've gathered for you here. I hope you find this newsletter to be a useful resource in your practice.

Heather Greene, MSN, FNP, AOCN®
The West Cancer Center
Memphis, Tennessee 

August 2016

Dear Colleague,

This is the third edition of our newsletter titled HER2-Positive Breast Cancer Updates. In this issue, we provide highlights that emanated from Perspectives in the Management of HER2-Positive Breast Cancer, a recent roundtable discussion held at the West Cancer Center in Memphis, Tennessee. Panelists discussed current topics such as neoadjuvant therapy and the emerging utilization of pathologic complete response rate. This edition also provides articles on topics such as the benefit of neoadjuvant therapy in early-stage HER2-postive breast cancer, the association of total pathologic complete response (tpCR) with event-free survival in HER-2 positive early breast cancer, and the role of the nurse practitioner in advancing patient care. Please share this newsletter with your colleagues and don’t hesitate to get in touch with me with your comments or suggestions through the editors of the Journal of the Advanced Practitioner in Oncology, or JADPRO, at editor@advancedpractitioner.com.

Until next time, take a look at the links I’ve gathered for you here. I hope you find this newsletter to be a useful resource in your practice.

Heather Greene, MSN, FNP, AOCN®
The West Cancer Center
Memphis, Tennessee  

June 2016

Dear Colleague,

This is the second edition of our newsletter titled HER2-Positive Breast Cancer Updates. In the issue, we provide valuable resources that emanated from the recent Annual Meeting of the American Society of Clinical Oncology. Included are articles on such topics as the benefit of neoadjuvant therapy in early-stage HER2-postive breast cancer, the predictive value of pathologic response rate (pcR), and an overview of an investigative trastuzumab biosimilar. Please share this newsletter with your colleagues and don’t hesitate to get in touch with me with your comments or suggestions through the editors of the Journal of the Advanced Practitioner in Oncology, or JADPRO, at editor@advanced practitioner.com at any time.

Until next time, take a look at the links I’ve gathered for you here. I hope you find this newsletter to be a useful resource in your practice.

Heather Greene, MSN, FNP, AOCN®
The West Cancer Center
Memphis, Tennessee  

May 2016

Dear Colleague,

It is predicted that just under a quarter of a million women in the United States will be diagnosed with breast cancer in 2016. Between 15% and 30% of those women will have tumors found to be positive for the growth-promoting protein HER2.

Although there are several FDA-approved agents available to target HER2 directly, there is still much that is unknown about predicting who will benefit from these drugs, knowing how to effectively combine them with traditional chemotherapy, finding optimal dosing and scheduling, and importantly, combatting the development of resistance in metastatic disease.

The Journal of the Advanced Practitioner in Oncology, or JADPRO, presents HER2-Positive Breast Cancer Updates, a monthly educational newsletter and enduring resource for advanced practitioners. As the editor of the program, I will share articles and news items containing the latest in treatment and management strategies. Next month, we’ll take a look at the most relevant and potentially practice-changing results to come out of the Annual Meeting of the American Society of Clinical Oncology.

Please feel free to share this newsletter with your colleagues, and don’t hesitate to get in touch with me with comments or suggestions through the JADPRO editors at editor@advancedpractitioner.com at any time.

Until next time, take a look at the links I’ve gathered for you here. I hope you find this to be a useful resource in your practice!

Heather Greene, MSN, FNP, AOCNP®
The West Cancer Center
Memphis, Tennessee

click me